RNS Number : 6515U
N4 Pharma PLC
27 January 2025

27 January 2025

N4 Pharma plc

("N4 Pharma" or the "Company")

Investor Webinar

N4 Pharma plc (AIM: N4P),the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that Nigel Theobald, Chief Executive Officer and Dr Alastair Smith, Non-Executive Director,will hold an investor presentation and Q&A session on Tuesday, 4 February 2025at 9.30 am via the Investor Meet Company platform.

The presentation will provide an overview of N4 Pharma and its lead programme, N4 101, a dual-targeting, orally delivered RNA therapeuticfor inflammatory bowel disease.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00 am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet N4 Pharma plc via:

https://www.investormeetcompany.com/n4-pharma-plc/register-investor

Investors who already follow N4 Pharma plc on the Investor Meet Company platform will automatically be invited.

- Ends -

For more information please contact:

N4 Pharma plc
Nigel Theobald, Chief Executive Officer
Luke Cairns, Executive Director

Via N4 Pharma Investor Hub
Sign up atinvestors.n4pharma.com

Investor questions on this announcement
We also invite investors to ask questions on this announcement via our investor hub

https://investors.n4pharma.com/link/VyENpe

SP Angel CorporateFinance LLP
Nominated Adviser and Joint Broker
Matthew Johnson/Jen Clarke (Corporate Finance)
Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)

Tel: +44 (0) 20 3470 0470

Turner Pope Investments (TPI) Limited Tel: +44 (0) 20 3657 0050
Joint Broker
Andy Thacker/James Pope

Northstar Communications Limited Tel: +44 (0) 113 730 3896
Investor Relations
Sarah Hollins

About N4 Pharma
N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases.

RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing,protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage.

N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners.

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.With an estimated 10 million people globally suffering from Crohn's disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments.

For further information on the Company visitwww.n4pharma.comor sign up athttps://investors.n4pharma.com/auth/signup.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAEAFFLADNSEFA